Axogen, Inc. Reports Second Quarter 2026 Financial Results
Axogen reported Q2 revenue of $69.7 million, up 23.1% year-over-year, driven by broad-based growth across Extremities, Oral Maxillofacial, and Breast segments. Adjusted net income was $7.3 million, or $0.12 per share, flat compared to the prior year, while GAAP results reflected a net loss of $1.5 million.
Key figures
- Revenue
- 69700000
- Guidance
- FY26 revenue at least $279 million (at least 24% growth); gross margin at least 73%; positive free cash flow
- Revenue Yoy
- 23.1%
- Adjusted eps
- 0.12
- Gross margin
- 72.7%
- Gross profit
- 50674000
- Adjusted ebitda
- 8400000
- Cash and investments
- 113400000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.